The DOPPS practice monitor for us dialysis care: Potential impact of recent guidelines and regulatory changes on management of mineral and bone disorder among us hemodialysis patients

American Journal of Kidney Diseases

Volumn 63, Issue 5, 2014, Pages 851-854

  Tentori, Francesca ^a   Fuller, Douglas S ^a   Port, Friedrich K ^a   Bieber, Brian A ^a   Robinson, Bruce M ^a   Pisoni, Ronald L ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS;

ARTICLE; BONE DISEASE; CALCIUM BLOOD LEVEL; CLINICAL PRACTICE; HEALTH CARE; HEALTH CARE FACILITY; HEMODIALYSIS PATIENT; HUMAN; MINERAL DEFICIENCY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; UNITED STATES;

BONE DISEASES, METABOLIC; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICARE; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION; RENAL DIALYSIS;

EID: 84898895449     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.02.003     Document Type: Article

References (7)

1. W.G. Goodman, J. Goldin, and B.D. Kuizon et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 2000 1478 1483
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 S130
3. K. Uhlig, J.S. Berns, and B. Kestenbaum et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD) Am J Kidney Dis 55 5 2010 773 799
4. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 suppl 3 2003 S1 S202
5. Centers for Medicare & Medicaid Services Medicare program; end-stage renal disease prospective payment system. Final rule Fed Regist 75 155 2010 49029 49214
6. US Government Accountability Office End-Stage Renal Disease: CMS Should Monitor Access to and Quality of Dialysis Care Promptly After Implementation of New Bundled Payment System 2010 US Government Accountability Office Washington, DC
7. F. Tentori, B.A. Bieber, and H. Morgenstern et al. Parathyroid hormone (PTH) levels rose over time in hemodialysis (HD) patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) [European Renal Association-European Dialysis and Transplant Association Congress (ERA-EDTA) abstract] Nephrol Dial Transplant 27 suppl 2 2012 ii52 ii54